fluorodeoxyglucose f18 has been researched along with HIV in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Avery, AK; Bowman, E; Durieux, JC; Funderburg, N; Hileman, CO; Janus, SE; Kettelhut, A; McComsey, GA; Nguyen, TT; Sullivan, C | 1 |
| Bertels, J; Coolen, T; De Tiège, X; Goffard, JC; Goldman, S; Henrard, S; Puttaert, D; Rovai, A; Slama, H; Trotta, N; Van Vooren, JP | 1 |
| Hyafil, F; Mikail, N; Sinigaglia, M | 1 |
| Ankrah, AO; Boshomane, TG; Lawal, IO; Lengana, T; Nyakale, NE; Popoola, GO; Reyneke, F; Sathekge, MM; Vorster, M | 1 |
| Ankrah, AO; Kaoma, CA; Lawal, IO; Maes, A; Mokgoro, NP; Mokoala, KMG; Popoola, GO; Sathekge, MM; Van de Wiele, C | 1 |
| Carrasquillo, JA; Dunleavy, K; Grant, N; Jaffe, ES; Little, RF; Pittaluga, S; Steinberg, SM; Wayne, AS; Wilson, WH; Yarchoan, R | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and HIV
| Article | Year |
|---|---|
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Child; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; HIV; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Positron-Emission Tomography; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Viral Load; Young Adult | 2010 |
5 other study(ies) available for fluorodeoxyglucose f18 and HIV
| Article | Year |
|---|---|
Heroin Use Is Associated With Vascular Inflammation in Human Immunodeficiency Virus.
Topics: Adult; Cross-Sectional Studies; Fluorodeoxyglucose F18; Heroin; HIV; HIV Infections; Humans; Inflammation; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Impact of Human Immunodeficiency Virus and Recreational Drugs on Cognitive Functions.
Topics: Adult; Brain; Cognition; Cognitive Dysfunction; Fluorodeoxyglucose F18; HIV; HIV Infections; Humans; Illicit Drugs; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Positron-Emission Tomography; Prospective Studies | 2023 |
Could FDG-PET imaging play a role in the detection of progressing atherosclerosis in HIV-infected patients?
Topics: Arteritis; Atherosclerosis; Cross-Sectional Studies; Fluorodeoxyglucose F18; HIV; HIV Infections; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2019 |
18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma.
Topics: Adult; Female; Fluorodeoxyglucose F18; HIV; Hodgkin Disease; Humans; Male; Positron-Emission Tomography; Prognosis; Risk Assessment | 2018 |
Prognostic Value of Pre-treatment F-18 FDG PET Metabolic Metrics in Patients with Locally Advanced Carcinoma of the Anus with and without HIV Infection.
Topics: Adult; Age Factors; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2018 |